Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment

E. Hollander; C. M. DeCaria; F. R. Schneier; H. A. Schneier; M. R. Liebowitz; D. F. Klein

Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment

E. Hollander, C. M. DeCaria, F. R. Schneier, H. A. Schneier, M. R. Liebowitz, D. F. Klein

Research output: Contribution to journal › Article › peer-review

Abstract

Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.

Original language	English (US)
Pages (from-to)	119-123
Number of pages	5
Journal	Journal of Clinical Psychiatry
Volume	51
Issue number	3
State	Published - Jan 1 1990
Externally published	Yes

ASJC Scopus subject areas

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{e28cfb82601f49858b447018b73f62ff,

title = "Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment",

abstract = "Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.",

author = "E. Hollander and DeCaria, {C. M.} and Schneier, {F. R.} and Schneier, {H. A.} and Liebowitz, {M. R.} and Klein, {D. F.}",

year = "1990",

month = jan,

day = "1",

language = "English (US)",

volume = "51",

pages = "119--123",

journal = "Diseases of the Nervous System",

issn = "0160-6689",

publisher = "Physicians Postgraduate Press Inc.",

number = "3",

}

TY - JOUR

T1 - Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment

AU - Hollander, E.

AU - DeCaria, C. M.

AU - Schneier, F. R.

AU - Schneier, H. A.

AU - Liebowitz, M. R.

AU - Klein, D. F.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.

AB - Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.

UR - http://www.scopus.com/inward/record.url?scp=0025240077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025240077&partnerID=8YFLogxK

M3 - Article

C2 - 2106515

AN - SCOPUS:0025240077

SN - 0160-6689

VL - 51

SP - 119

EP - 123

JO - Diseases of the Nervous System

JF - Diseases of the Nervous System

IS - 3

ER -

Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this